MYC and medulloblastoma: Of these, Group 3 medulloblastoma represents the most aggressive subgroup (with < 60% overall survival) which often exhibits MYC amplification or overexpression (17–20% of cases), metastasis (40–50% of cases), and treatment resistance [6–8].